论文部分内容阅读
目的:研究扶正消癌Ⅰ号方对GP方案治疗老年非小细胞肺癌(NSCLC)的减毒增效作用。方法:选择2006年1月—2006年12月住院的老年NSCLC患者35例,按随机设计分为研究组和对照组,分别为20例和15例,研究组给予扶正消癌Ⅰ号方,药用:茯苓10g,白术10g,山药10g,黄芪15g,太子参15g,白花蛇舌草30g,山慈菇15g,蜈蚣2条,每日1剂,连服14天,同时给予GP方案:吉西他滨(GEM)1000mg/m2,第1,8天,卡铂(CBP)AUC 5,第1天,3周为1个周期,至少完成2个周期治疗的病例进入统计学处理,对照组给予GP方案,方法同研究组,观察近期疗效,毒副反应,生存质量(QOL)和总生存时间(OS)。结果:进入统计学处理的病例数研究组与对照组分别为18例和13例,研究组与对照组在近期疗效方面无显著差异(44.44%vs 38.46%,χ2=0.111,P=0.739),研究组毒副反应发生率显著低于对照组(P<0.05)、QOL优于对照组(P<0.05),在中位生存时间(MST)和OS方面无显著性差异(P>0.05)。结论:扶正消癌Ⅰ号方对GP方案治疗老年NSCLC患者能够显著降低毒副反应发生率,提高QOL,具有肯定的减毒增效作用,有一定的临床应用价值。
Objective: To study the attenuating and synergistic effect of Fuzhengxiao Cancer Ⅰ on GP regimen in the treatment of elderly non-small cell lung cancer (NSCLC). Methods: A total of 35 elderly NSCLC patients hospitalized from January 2006 to December 2006 were randomly divided into study group and control group, 20 and 15 respectively. Use: Poria 10g, Atractylodes 10g, yam 10g, Astragalus 15g, heterophylla 15g, Hedyotis diffusa 30g, Capsicum 15g, centipede 2, day 1, and even served 14 days, given GP program: gemcitabine GEM) 1000mg / m2, the first and eighth days, carboplatin (CBP) AUC5, the first day, three weeks for a cycle, at least complete the two cycles of treatment into the statistical treatment of cases, the control group given GP regimen, Methods with the study group, observe the short-term efficacy, toxicity, quality of life (QOL) and total survival time (OS). Results: There were 18 cases and 13 cases in the study group and the control group, respectively. There was no significant difference in the short term efficacy between the study group and the control group (44.44% vs 38.46%, χ2 = 0.111, P = 0.739) There was no significant difference in median survival time (MST) and OS between the two groups (P> 0.05). Conclusion: Fuzheng Xiaohua Decoction Ⅰ can significantly reduce the incidence of toxic and side effects and improve QOL in patients with elderly NSCLC treated with GP regimen, which has positive effect of attenuating toxicity and synergism and has certain clinical value.